Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
13 Feb
Blueprint Medicines Corp reports results for the quarter ended December 31 - Earnings Summary
  • Blueprint Medicines Corp BPMC.OQ reported a quarterly adjusted loss of 79 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.82. The mean expectation of twenty analysts for the quarter was for a loss of 70 cents per share. Wall Street expected results to range from $-1.24 to -51 cents per share.

  • Revenue rose 103.4% to $146.37 million from a year ago; analysts expected $145.84 million.

  • Blueprint Medicines Corp's reported EPS for the quarter was a loss of 79 cents​.

  • The company reported a quarterly loss of $49.96 million.

  • Blueprint Medicines Corp shares had risen by 18.7% this quarter.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 0.9% in the last three months.​

  • In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 5 "hold" and 1 "sell" or "strong sell."

  • The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Blueprint Medicines Corp is $128.50

This summary was machine generated from LSEG data February 13 at 03:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Dec. 31 2024

-0.70

-0.79

Missed

Sep. 30 2024

-0.97

-0.89

Beat

Jun. 30 2024

-1.29

-0.80

Beat

Mar. 31 2024

-1.66

-1.32

Beat

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10